Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
6 authors.
Kemal C GogebakanDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington; kgogebak@fredhutch.org.
Natalia KunstCancer Outcomes, Public Policy, and Effectiveness Research Center, Yale School of Medicine, New Haven,Connecticut.
Alireza GhodsiDivision of Nuclear Medicine, Department of Radiology, University of Washington School of Medicine, Seattle, Washington; and.
Lukas OwensDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
Amir IravaniDivision of Nuclear Medicine, Department of Radiology, University of Washington School of Medicine, Seattle, Washington; and.
Ruth EtzioniDivision of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
Funding
TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Modeling Precision Interventions for Prostate Cancer ControlU01CA253915 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ETZIONI, RUTH D, TSODIKOV, ALEXANDER · 2020 to 2025
$6.5M
Modeling and analytics for cancer diagnostics: traversing the data-evidence divideR35CA274442 · NCI · FRED HUTCHINSON CANCER CENTER · PI RUTH D ETZIONI · 2022 to 2026
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Cost-Effectiveness Analysis of · full record | OpenQuestion